NASDAQ:GLMD

Galmed Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy GLMD

*Your capital is at risk

$0.680

-0.0111 (-1.61%)

At Close: Jun 03, 2026

Galmed Pharmaceuticals Q1 EPS $(0.17) Beats $(0.2) Estimate

12:00am, Tuesday, 07'th May 2019

Galmed Pharma Says it Has Reached an Agreement with the FDA on Key Aspects of its Phase 3/4 ARMOR Study

12:00am, Tuesday, 09'th Apr 2019

Galmed And Aramchol In NASH, And The Market Assessment

12:00am, Thursday, 28'th Mar 2019

56 Stocks Moving In Thursday's Mid-Day Session

12:00am, Thursday, 14'th Mar 2019

Galmed Pharmaceuticals Q4 EPS $(0.18) Misses $(0.13) Estimate

12:00am, Wednesday, 13'th Mar 2019

Galmed Reports 'Positive' Results From Pharmacokinetic Split Dose Study Of Aramchol

12:00am, Tuesday, 12'th Mar 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

12:00am, Sunday, 10'th Mar 2019

Galmed And Aramchol In NASH: Moving On Higher

12:00am, Tuesday, 05'th Mar 2019

52 Biggest Movers From Yesterday

12:00am, Thursday, 13'th Dec 2018

Galmed Pharmaceuticals shares are trading up 10.5% after B. Riley initiated coverage on the stock with a Buy rating and a price target of $28.

12:00am, Wednesday, 12'th Dec 2018

Ibex Investors LLC Buys Silicom, Lithium Americas Corp, General Motors Co, Sells Mellanox ...

12:00am, Wednesday, 21'st Nov 2018

Galmed: A Deep-Dive Analysis Of The ARREST Trial

12:00am, Friday, 16'th Nov 2018

Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare ...

12:00am, Wednesday, 14'th Nov 2018

Galmed Pharmaceuticals Stock News

Galmed Pharmaceuticals Q1 EPS $(0.17) Beats $(0.2) Estimate

Galmed Pharma Says it Has Reached an Agreement with the FDA on Key Aspects of its Phase 3/4 ARMOR Study

Galmed And Aramchol In NASH, And The Market Assessment

56 Stocks Moving In Thursday's Mid-Day Session

Galmed Pharmaceuticals Q4 EPS $(0.18) Misses $(0.13) Estimate

Galmed Reports 'Positive' Results From Pharmacokinetic Split Dose Study Of Aramchol

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Galmed And Aramchol In NASH: Moving On Higher

52 Biggest Movers From Yesterday

Galmed Pharmaceuticals shares are trading up 10.5% after B. Riley initiated coverage on the stock with a Buy rating and a price target of $28.

Ibex Investors LLC Buys Silicom, Lithium Americas Corp, General Motors Co, Sells Mellanox ...

Galmed: A Deep-Dive Analysis Of The ARREST Trial

Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare ...

Galmed Announces Phase 2 Data for Aramchol in NASH Presented During Late-Breaking Abstract Oral Session of The Liver Meeting 2018

5 Stocks Moving In Monday's After-Hours Session

Top Fintech Company